Molecular Diagnostics 2019

Dr. Cobb is the acting Director for Clinical Molecular Diagnostics at Roche Diagnostics Corporation where he serves in a scientific advisory role supporting the laboratory scientific community. He obtained his Ph.D. in Medical Genetics at the University of Alabama at Birmingham ... and trained as a postdoctoral fellowship at Georgetown University Institute for Molecular Genetics. He then completed an American Board of Medical Genetics fellowship program at the National Institutes of Health (NIH) in the National Human Genome Research Institute and is a board certified diplomat of the American College of Medical Genetics. Previously, he was the Head of Scientific Affairs for the global organization where he was responsible for the molecular portfolio's medical plans. He has over 15 years of experience in diagnostics and serves on several international scientific committees and working groups.

Dr. Shawn C. Baker is the Chief Science Officer and co-founder of AllSeq. Having received his Ph.D. at the University of California - Davis, he started his career as a Research Scientist at Illumina when it was a 15-person startup. After spending several years at the bench ... developing gene expression array products, he transitioned to Product Marketing where he led a team in charge of Illuminas Expression and Regulation sequencing portfolio. In 2013 Dr. Baker co-founded AllSeq, establishing the only true sequencing marketplace, matching researchers with service providers based on their needs.

Dr. Emily Hollister is a microbial ecologist and serves as the Vice President for Information Technology & Analytics at Diversigen, Inc. Prior to joining Diversigen, Dr. Hollister served as an Assistant Professor in the Department of Pathology & Immunology at Baylor College of ... Medicine and as the Director of Microbial Ecology and Bioinformatics at the Texas Children's Microbiome Center at Texas Children's Hospital. Her microbiome experience ranges from soils and biofuel production systems to the human microbiome, built environment, and pre-clinical models of disease.

Dr. Christopher Mason completed his dual B.S. in Genetics and Biochemistry (2001) from University of Wisconsin-Madison, his Ph.D. in Genetics (2006) from Yale University, and then completed post-doctoral training in clinical genetics (2009) at Yale Medical School, and a joint ... post-doctoral Fellow of Genomics, Ethics, and Law at Yale Law School (2009). He is currently an Associate Professor at Weill Cornell Medicine, with appointments at the Tri-Institutional Program on Computational Biology and Medicine, the Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute. The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and human physiology. We create and explore novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods, to ensure clinical-quality genome measurements/editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which establish the molecular foundations and genetic defenses for enabling long-term human space travel. He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He has >130 peer-reviewed papers that have been featured on the covers of Nature, Science, Cell Host and Microbe, Nature Biotechnology, Nature Microbiology, and many others.He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y.

Eugean Jiwanmall's past professional experiences include basic science and clinical research. In his current role as a Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross' Claim Payment Policy Department within Facilitated Health ... Networks, he has served as the subject-matter-expert, writer, reviewer, communicator, presenter, consultant, & decision-maker for hundreds of medical policy topics & technology assessments within dozens of clinical disciplines & multiple business areas. Eugean is finishing graduate work in bioethics at the University of Pennsylvania School of Medicine. He holds a bachelor's degree in biological sciences with honors from Drexel University (minor was in business administration), a master's degree of public health in evaluative clinical sciences from Dartmouth Medical School, and an MBA in health care management and economics with honors from Drexel University.

Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ... breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.